RNS Announcements

2026

2025

2024

2023

2022

2026

23 June

Result of AGM

01 June

New Partnership Agreement in Slovakia

29 May

Notice of Annual General Meeting

26 May

New Strategic Alliance in Spain and Portugal

30 March

Final Results and Investor Presentation

16 March

Notice of Results and Investor Presentation

17 February

PDMR Shareholding

16 February

Statement regarding Share Price Movement

05 February

Holding(s) in Company

04 February

Director/PDMR Shareholding

21 January

Trading Update

2025

03 November

Move from Access to Apex Segment of Aquis

23 October

Appointment of Aquis Corporate Adviser

20 October

New Commercial Partnership in Australia

14 October

Director/PDMR Shareholding

14 October

New Commercial Partnership in Sweden

13 October

Q3 2025 Trading Update and Grant of Options

08 September

Unaudited Interim Results to 30 June 2025

15 July

Trading Update and Notice of Results

27 June

Result of AGM and Notice of Trading Update

09 June

PDMR Shareholding

05 June

Notice of Annual General Meeting - Clarification

30 May

Director/PDMR Shareholdings

30 May

Notice of Annual General Meeting

29 May

Final Results

07 May

Notice of Results and Investor Presentation

28 March

New Partnership Agreement in South Korea

20 February

Grant of Options

20 February

Major new Supply Agreement in the Far East

23 January

Trading Update

2024

05 November

Director/PDMR Shareholding

01 November

Result of Requisitioned General Meeting

15 October

Publication of Circular and Notice of Requisitioned General Meeting

10 October

New Commercial Partnership in Mexico

08 October

Q3 2024 Trading Update

07 October

Appointment of Non-Executive Director

03 October

New Commercial Partnership in Ukraine

30 September

Total Voting Rights

27 September

Holding(s) in Company

25 September

Response to General Meeting Requisition

25 September

General Meeting Requisition Notice

16 September

New Commercial Partnership in Greece

06 September

Response to OptiBiotix Health plc announcement

04 September

Share Subscription and Proposed Board Appointment

30 August

Unaudited Interim Results to 30 June 2024

15 August

New commercial partnership agreement in China

08 August

Result of AGM

29 July

New appointment

15 July

Six month trading update

28 June

Final Results

26 February

Partner agreement with SymbioPharm

09 February

Change of auditor

31 January

New appointment

11 January

Directorate change

2023

27 September

Unaudited Results to 30 June 2023

01 August

Distribution agreement

26 July

Result of AGM

24 July

New appointment

28 June

Final Results

04 January

Commercial and scientific update

2022

28 September

Unaudited Results to 30 June 2022

14 September

New commercialisation partner in Asia Pacific

14 June

Appointment of Chief Executive Officer

31 May

Launch of cholesterol reducing yoghurt

19 April

Change of registered office

01 April

Holding(s) in Company

31 March

Admission to trading on AQSE and first day of dealings

23 June 2026

Result of AGM

01 June 2026

New Partnership Agreement in Slovakia

29 May 2026

Notice of Annual General Meeting

Aquis-listed ProBiotix Health taps into demand for cardiovascular disease treatments
Stephen O'Hara | 23 February 2023
IG UK | Youtube

Sign up for Investor Alerts

Investor Alert